Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 3:12:661578.
doi: 10.3389/fneur.2021.661578. eCollection 2021.

Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease

Affiliations
Review

Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease

Brandon M Fox et al. Front Neurol. .

Erratum in

Abstract

Moyamoya disease (MMD) and moyamoya syndrome (MMS) are progressive vascular pathologies unique to the cerebrovasculature that are important causes of stroke in both children and adults. The natural history of MMD is characterized by primary progressive stenosis of the supraclinoid internal carotid artery, followed by the formation of fragile collateral vascular networks. In MMS, stenosis and collateralization occur in patients with an associated disease or condition. The pathological features of the stenosis associated with MMD include neointimal hyperplasia, disruption of the internal elastic lamina, and medial attenuation, which ultimately lead to progressive decreases in both luminal and external arterial diameter. Several molecular pathways have been implicated in the pathophysiology of stenosis in MMD with functions in cellular proliferation and migration, extracellular matrix remodeling, apoptosis, and vascular inflammation. Importantly, several of these molecular pathways overlap with those known to contribute to diseases of systemic arterial stenosis, such as atherosclerosis and fibromuscular dysplasia (FMD). Despite these possible shared mechanisms of stenosis, the contrast of MMD with other stenotic pathologies highlights the central questions underlying its pathogenesis. These questions include why the stenosis that is associated with MMD occurs in such a specific and limited anatomic location and what process initiates this stenosis. Further investigation of these questions is critical to developing an understanding of MMD that may lead to disease-modifying medical therapies. This review may be of interest to scientists, neurosurgeons, and neurologists involved in both moyamoya research and treatment and provides a review of pathophysiologic processes relevant to diseases of arterial stenosis on a broader scale.

Keywords: angiopathy; cerebrovascular; moyamoya; stenosis; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of the paradigmatic progression pattern of arterial stenosis in moyamoya on the macroscopic (A–C) and microscopic (D–F) scale. (A,D) Normal terminal ICA. (B,E) Early in the progression of moyamoya, intimal hyperplasia leads to the development of luminal stenosis without a significant change in the outer diameter of the arterial segment. (C,F) As luminal stenosis continues to progress in moyamoya, attenuation of the medial layer of the artery leads to a reduction in the outer arterial diameter. Used with permission from Barrow Neurological Institute, Phoenix, Arizona.

References

    1. Suzuki J, Takaku A. Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. (1969) 20:288–99. 10.1001/archneur.1969.00480090076012 - DOI - PubMed
    1. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. (2009) 360:1226–37. 10.1056/NEJMra0804622 - DOI - PubMed
    1. Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK. Progression of unilateral moyamoya disease: a clinical series. Cerebrovasc Dis. (2006) 22:109–15. 10.1159/000093238 - DOI - PubMed
    1. Kuroda S, Ishikawa T, Houkin K, Nanba R, Hokari M, Iwasaki Y. Incidence and clinical features of disease progression in adult moyamoya disease. Stroke. (2005) 36:2148–53. 10.1161/01.STR.0000182256.32489.99 - DOI - PubMed
    1. Kawano T, Fukui M, Hashimoto N, Yonekawa Y. Follow-up study of patients with “unilateral” moyamoya disease. Neurol Med Chir (Tokyo). (1994) 34:744–7. 10.2176/nmc.34.744 - DOI - PubMed

LinkOut - more resources